Comparative Pharmacology
Head-to-head clinical analysis: LEVOLET versus LEVOXYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOLET versus LEVOXYL.
LEVOLET vs LEVOXYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levolet (levothyroxine) is a synthetic thyroid hormone that replaces endogenous thyroxine (T4). It is converted to triiodothyronine (T3) in peripheral tissues, which binds to thyroid hormone receptors to regulate gene expression, increasing metabolic rate and protein synthesis.
Levothyroxine is a synthetic thyroid hormone (T4) that is deiodinated to triiodothyronine (T3) in peripheral tissues, binding to thyroid hormone receptors in the nucleus and increasing metabolic rate, protein synthesis, and oxygen consumption.
Levofloxacin 500 mg orally or intravenously once daily for 5-14 days depending on indication.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 6-8 weeks based on TSH. Maintenance dose: 50-200 mcg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; shorter in patients with hepatic impairment.
6-7 days in euthyroid patients; prolonged in hypothyroidism (9-10 days), shortened in hyperthyroidism (3-4 days); clinical steady-state after 6-8 weeks of consistent dosing.
Renal: 70-80% unchanged, biliary/fecal: 20-30% as metabolites.
Renal (30-50% as unchanged drug and conjugates); fecal (biliary, 20-40% as conjugates); total clearance approximates 1-2 L/day in euthyroid patients.
Category C
Category C
Thyroid Hormone
Thyroid Hormone